Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 04/15/20
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal FilmGlobeNewsWire • 02/10/20
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis TreatmentGlobeNewsWire • 02/06/20
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 GuidanceGlobeNewsWire • 01/10/20
Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure ClustersGlobeNewsWire • 12/02/19
Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALSGlobeNewsWire • 11/13/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/09/19
Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019GlobeNewsWire • 10/15/19
Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)GlobeNewsWire • 09/30/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/11/19
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2018 Results - Earnings Call TranscriptSeeking Alpha • 03/15/19